Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | angiotensin II receptor, type 1 | No references | |
Homo sapiens | angiotensin II receptor, type 2 | Starlite/ChEMBL | No references |
Homo sapiens | neuropeptide Y receptor Y5 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | angiotensin II receptor, type 1 | 359 aa | 403 aa | 19.1 % |
Echinococcus granulosus | pyroglutamylated rfamide peptide receptor | angiotensin II receptor, type 2 | 363 aa | 398 aa | 18.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0325 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0325 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0325 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0288 | 0.7743 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0201 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0325 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0325 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0325 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0161 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0325 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0288 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0161 | 0 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0325 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0325 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0325 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0325 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0325 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0201 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0325 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0325 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0325 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0325 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0325 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0325 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0325 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0325 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0325 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0325 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0164 | 0.0151 | 0.0151 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 44 nM | Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cells | ChEMBL. | 10866375 |
IC50 (functional) | = 44 nM | Antagonistic activity against neuropeptide Y receptor type 5 subtype stably expressed in LM(tk-)cells | ChEMBL. | 10866375 |
Inhibition (functional) | = 63 % | In vivo inhibition of angiotensin II (0.1 ug/kg) induced increase in blood pressure in conscious male rat at 3 mg/kg for 3h/7h. | ChEMBL. | 8510105 |
Kd (binding) | = 8.32 | Displacement of angiotensin II from angiotensin II receptor of rabbit aorta | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.